{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2","upperLimit":"13","value":"6.5"}]}],"title":"Total # of cycles"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"11","value":"2"}]}],"title":"# of cycles at 2.5 mg/kg^2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"11","value":"3"}]}],"title":"# of cycles at 1.9 mg/kg^2"}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"Treatment characteristics: Dosing patterns - Number of cycles of treatment with BLENREP therapy - From Treatment initiation to treatment discontinuation or last dose during study period.","dispersionType":"Full Range","groups":[{"description":"Participants with relapsed and/or refractory multiple myeloma who were treated with Belantamab Mafodotin - blmf (BLENREP) in the DCI Oncology outpatient clinics between August 5, 2020 and November 7, 2023","id":"OG000","title":"Multiple Myeloma/Blenrep Participants"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.","title":"Treatment Characteristics: Dosing Patterns - Number of Cycles of Treatment With BLENREP Therapy","type":"PRIMARY","unitOfMeasure":"Cycles"}